Clinical effectiveness of tandospirone citrate (5-HT1A agonist) on patients with progressive supranuclear palsy

Clinical Neurology

Volumn 42, Issue 1, 2002, Pages 42-44

  Fujino, Yasuhiro ^a   Nakajima, Masashi ^a   Tsuboi, Yoshio ^a   Baba, Yasuhiko ^a   Yamada, Tatsuo ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT; Extrapyramidal sign; Progressive supranuclear palsy; Tandospirone citrate

Indexed keywords

SEROTONIN 1A AGONIST; TANDOSPIRONE;

APRAXIA; ARTICLE; BASAL GANGLION; BLADDER DYSFUNCTION; BRADYKINESIA; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; DYSARTHRIA; DYSPHAGIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; EYELID DISEASE; FEMALE; GAIT DISORDER; GAZE PARALYSIS; HUMAN; LIVER DYSFUNCTION; MALE; PROGRESSIVE SUPRANUCLEAR PALSY; VERTIGO;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; PIPERAZINES; PYRIMIDINES; SEROTONIN AGONISTS; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 0036389361     PISSN: 0009918X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Litvan I, Agid Y, Calne D, et al: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP International Workshop. Neurology 47 : 1-9, 1996
2. Jackson JA, Jankovic J, Ford J: Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol 13 : 273-278, 1983
3. Hornykiewicz O, Shannak K: Brain monoamines in progressive supranuclear palsy-comparison with idiopathic Parkinson's disease. J Neural Transm Suppl 42 : 219-227, 1994
4. Steur EN: Increase of Parkinson disability after fluoxetine medication. Neurology 43 : 211-213, 1993
5. Rafal RD, Grimm RJ: Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents. Neurology 31 : 1507-1518, 1981